Is Samsung Biologics profitable in 2026?

Yes. H1 2026 operating profit was KRW 1,167 billion on revenue of KRW 2,578 billion, an operating margin around 45%. Q2 2026 revenue rose 30% YoY to KRW 1,320.9 billion with operating profit up 23% YoY to KRW 586.4 billion, per its July 22, 2026 earnings release.

Who is Samsung Biologics' biggest competitor?

Lonza Group is the CDMO market leader by revenue (~$8.14B in 2024 vs Samsung's ~$3.28B), per Statista data cited July 2025. Lonza also commands a reported 15-20% pricing premium via proprietary platforms like GS System, per Korean trade press in June 2026.

Could AI replace Samsung Biologics?

No. Its revenue depends on physical, regulated GMP manufacturing (785,000L validated capacity, 428+ cumulative regulatory approvals as of 2025). Samsung Biologics uses AI internally for digital twins and documentation to boost manufacturing efficiency, not to replace core biologics production, per company technical materials from 2025-2026.

Who owns Samsung Biologics?

Samsung Biologics is publicly listed on the Korea Exchange (KRX: 207940) since 2016 and sits within the Samsung Group conglomerate structure. The National Pension Service holds roughly 8.13% as a major shareholder, per background reporting.

Is Samsung Biologics growing faster than WuXi Biologics?

By revenue scale, Samsung Biologics (~$3.28B in 2024) was already ahead of WuXi Biologics (~$2.59B), per Statista data from 2025. Samsung Biologics has also launched a platform-licensing unit in 2026 to capture clients reportedly pressured by a new US biosecurity law affecting WuXi.

Biotech tools companies · subsidiary of Samsung Group · South Korea

Samsung Biologics

samsungbiologics.com ↗

Korean company that manufactures biologic drugs under contract for big pharma clients.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Q3 2026 earnings, first quarter to show cost impact of the ongoing labor strike

The call

Revenue and margins are climbing on full plants and a top-tier client list, while a live wage strike and a big pending acquisition sit as the near-term things to watch.

Samsung Biologics manufactures injectable drugs (biologics) for the world's largest pharmaceutical companies. It is difficult to copy because it has spent over a decade building massive factories approved by regulators, and pharmaceutical companies are locked in once they choose a manufacturer since switching requires re-approving their drug from scratch with regulators. The company is growing fast and making strong profits, but a labor strike that started in May 2026 is cutting into earnings this quarter, and the company's planned purchase of a peptide manufacturer could face delays if shareholders don't approve it.

Why

AI pressure: None apparent. AI drug discovery could someday change which molecules get made, but manufacturing scale-up still needs physical plants like Samsung's. Could AI do the core job? Unlikely.

Bigger players: Lonza, Fujifilm Diosynth. Lonza and Fujifilm run competing large-scale biologics plants and chase the same top pharma clients for new contracts. Could a giant copy it? No, they are blocked.

What protects it. Customers embed a specific plant into their FDA filing, so switching makers means refiling, which few companies want to redo.

What would change this call

Q3 2026 earnings show strike-driven margin or delivery impact. Would show whether the labor dispute is denting operational performance.
PolyPeptide tender offer reaches or fails the two-thirds shareholder acceptance threshold. Would show whether the CHF 1.46B peptide/GLP-1 expansion proceeds or collapses.
A top-20 biopharma customer publicly shifts a major program to Lonza or Fujifilm Diosynth. Would show real share loss to a named rival rather than cyclical noise.

Key numbers

785,000L total validated manufacturing capacity (2025-12-31)
Q2 2026 revenue up 30% year over year (2026-06-30)
428+ cumulative regulatory approvals earned (2025-12-31)

Named risks

Ongoing labor strike since May 2026 expected to hit Q3 2026 profitability. Severity: high
Wide wage gap (14%+ base plus 20% profit-sharing vs 6.2% offered) remains unresolved as of Jul 2026. Severity: medium
PolyPeptide acquisition requires two-thirds shareholder acceptance and multi-jurisdiction regulatory clearance. Severity: medium
Union left Samsung Group bargaining body in Jun 2026, raising odds of prolonged independent negotiations. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Lonza	contesting	Lonza leads CDMO revenue (~$8.14B, 2024) and raised 2025 guidance to 20-21% growth, per Jul 2025 report
WuXi Biologics	gaining on	Samsung launched IP licensing unit in Jun 2026 to capture share as US biosecurity law pressures WuXi
Thermo Fisher Scientific	losing to	Thermo Fisher ranked ahead of Samsung Biologics in 2024 CDMO revenue (~$7B vs ~$3.28B)
Catalent (Novo Holdings)	contesting	Catalent absorbed into Novo Holdings after ~$16.5B deal closed late 2024, reshaping CDMO field

Questions people ask

Is Samsung Biologics profitable in 2026?: Yes. H1 2026 operating profit was KRW 1,167 billion on revenue of KRW 2,578 billion, an operating margin around 45%. Q2 2026 revenue rose 30% YoY to KRW 1,320.9 billion with operating profit up 23% YoY to KRW 586.4 billion, per its July 22, 2026 earnings release.
Who is Samsung Biologics' biggest competitor?: Lonza Group is the CDMO market leader by revenue (~$8.14B in 2024 vs Samsung's ~$3.28B), per Statista data cited July 2025. Lonza also commands a reported 15-20% pricing premium via proprietary platforms like GS System, per Korean trade press in June 2026.
Could AI replace Samsung Biologics?: No. Its revenue depends on physical, regulated GMP manufacturing (785,000L validated capacity, 428+ cumulative regulatory approvals as of 2025). Samsung Biologics uses AI internally for digital twins and documentation to boost manufacturing efficiency, not to replace core biologics production, per company technical materials from 2025-2026.
Who owns Samsung Biologics?: Samsung Biologics is publicly listed on the Korea Exchange (KRX: 207940) since 2016 and sits within the Samsung Group conglomerate structure. The National Pension Service holds roughly 8.13% as a major shareholder, per background reporting.
Is Samsung Biologics growing faster than WuXi Biologics?: By revenue scale, Samsung Biologics (~$3.28B in 2024) was already ahead of WuXi Biologics (~$2.59B), per Statista data from 2025. Samsung Biologics has also launched a platform-licensing unit in 2026 to capture clients reportedly pressured by a new US biosecurity law affecting WuXi.

Timeline

2026-07-22Reports Q2 2026 revenue KRW 1,320.9B, up 30% YoY, operating profit KRW 586.4B
2026-07-19Announces CHF 1.46B all-cash tender offer to acquire PolyPeptide Group AG
2026-07-14Labor Relations Commission rejects union unfair-labor-practice claim
2026-06-30Daol Investment & Securities cuts price target citing strike and Q3 impact
2026-06-28Union votes 96.5% to leave Samsung Group super-enterprise bargaining body
2026-06-01Company reports record-low 1.9% employee turnover for 2025
2026-05-06Union begins ongoing legal compliance strike after full walkout
2026-05-01Full-scale union walkout runs May 1 to May 5
2025-08-17Raises FY2025 growth guidance from 20-25% to 25-30%
2025-07-23Reports Q2 2025 results and FY2024 revenue of ~$3.3B, up 23% YoY

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE